Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Life sciences
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
About
Home
NICE guidance
In development
Guidance, NICE advice and quality standards
In development
Skip to filters
Skip to results
Published
In consultation
In development
Awaiting development
Topic selection
Filter (2 active)
Skip to results
Filter by title or keyword
Filter
Expected publication date
Expected publication date
From date
To date
Apply date filters
Area of interest
Area of interest
COVID-19 (5)
Type
(
1 selected
)
Type
Guidance (295)
Guidance programme
(
1 selected
)
Guidance programme
Clinical guidelines (27)
Diagnostics guidance (9)
Health technology evaluations (11)
Highly specialised technologies guidance (8)
Interventional procedures guidance (15)
Medical technologies guidance (13)
NICE guidelines (30)
Public health guidelines (1)
Technology appraisal guidance (295)
Apply filters
Showing 201 to 250 of 295
Sort by
Title
Date
Apply sorting
Type: Guidance
Remove Type: Guidance filter
Guidance programme: Technology appraisal guidance
Remove Guidance programme: Technology appraisal guidance filter
Guidance, NICE advice and quality standards in development
Title
Type
Expected publication date
Pembrolizumab with lenvatinib for untreated PD-L1 positive recurrent or metastatic squamous cell head and neck cancer [ID5118]
Technology appraisal guidance
TBC
Pembrolizumab with olaparib for maintenance treatment of advanced squamous non-small-cell lung cancer [ID4006]
Technology appraisal guidance
TBC
Pembrolizumab with olaparib for maintenance treatment of non-squamous metastatic non-small-cell lung cancer after pembrolizumab with platinum-based chemotherapy [ID4028]
Technology appraisal guidance
TBC
Pembrolizumab with olaparib for treating hormone-relapsed metastatic prostate cancer after abiraterone or enzalutamide and chemotherapy [ID3814]
Technology appraisal guidance
TBC
Pembrolizumab with pemetrexed and platinum-based chemotherapy for previously TKI-treated EGFR-positive metastatic non-squamous non-small-cell lung cancer [ID3873]
Technology appraisal guidance
TBC
Pembrolizumab with pemetrexed and platinum-based chemotherapy for untreated unresectable advanced malignant pleural mesothelioma ID4044
Technology appraisal guidance
TBC
Pembrolizumab with platinum chemotherapy, pemetrexed and lenvatinib for untreated advanced non-squamous non-small-cell lung cancer [ID3985]
Technology appraisal guidance
TBC
Pembrolizumab with trastuzumab and chemotherapy for untreated HER2-positive advanced gastric or gastro-oesophageal junction cancer [ID3742]
Technology appraisal guidance
TBC
Pembrolizumab–vibostolimab with etoposide and platinum-based chemotherapy for untreated extensive-stage small-cell lung cancer [ID6361]
Technology appraisal guidance
TBC
Pemigatinib for treating myeloid or lymphoid neoplasms with a FGFR1 rearrangement [ID6172]
Technology appraisal guidance
TBC
Pertuzumab–trastuzumab with chemotherapy for treating HER2-positive breast cancer [ID2724]
Technology appraisal guidance
TBC
Pirtobrutinib for treating chronic lymphocytic leukaemia or small lymphocytic lymphoma after 1 or more BTK inhibitors [ID6269]
Technology appraisal guidance
TBC
Pirtobrutinib for treating relapsed or refractory mantle cell lymphoma [ID3975]
Technology appraisal guidance
TBC
Pirtobrutinib for untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID6397]
Technology appraisal guidance
TBC
Pitolisant for treating narcolepsy in children and young people 6 to 17 years ID6353
Technology appraisal guidance
TBC
Port Delivery System with ranibizumab for treating wet age-related macular degeneration [ID3983]
Technology appraisal guidance
TBC
Pralsetinib for thyroid cancer [ID4018]
Technology appraisal guidance
TBC
Quizartinib for induction, consolidation and maintenance treatment of newly diagnosed FLT3-ITD-positive acute myeloid leukaemia [ID4042]
Technology appraisal guidance
16 October 2024
Regorafenib for treating advanced gastrointestinal stromal tumours [ID1056]
Technology appraisal guidance
15 November 2017
Relugolix for treating hormone-sensitive prostate cancer [ID6187]
Technology appraisal guidance
TBC
Relugolix–estradiol–norethisterone acetate for treating pain associated with endometriosis [ID3982]
Technology appraisal guidance
TBC
Renal cell carcinoma Pathways Pilot [ID6186]
Technology appraisal guidance
TBC
Ribociclib in combination with endocrine therapy and goserelin for previously untreated hormone receptor-positive, HER2-negative advanced breast cancer in premenopausal women (ID1307)
Technology appraisal guidance
TBC
Ribociclib with an aromatase inhibitor for adjuvant treatment of hormone receptor-positive, HER2-negative early breast cancer [ID6153]
Technology appraisal guidance
TBC
Risankizumab for previously treated moderately to severely active ulcerative colitis in people aged 16 and over ID6209
Technology appraisal guidance
TBC
Rivogenlecleucel for treating haematological cancers in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1601]
Technology appraisal guidance
TBC
Rivogenlecleucel for treating haematological non-malignant diseases in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1496]
Technology appraisal guidance
TBC
Ropeginterferon alfa-2b for treating polycythaemia vera without symptomatic splenomegaly [ID1596]
Technology appraisal guidance
TBC
Rozanolixizumab for treating antibody-positive generalised myasthenia gravis [ID5092]
Technology appraisal guidance
TBC
Rucaparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy [ID5100]
Technology appraisal guidance
21 August 2024
Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer (Review of TA611) [ID4069]
Technology appraisal guidance
12 June 2024
Ruxolitinib for treating acute graft versus host disease refractory to corticosteroids in people aged 12 and over [ID6377]
Technology appraisal guidance
TBC
Ruxolitinib for treating non-segmental vitiligo in people 12 years and over [ID3998]
Technology appraisal guidance
31 July 2024
Sacituzumab govitecan for treating advanced non-small-cell lung cancer after platinum-based chemotherapy and a PD-1 or PD-L1 inhibitor [ID6375]
Technology appraisal guidance
TBC
Sacituzumab govitecan for treating hormone receptor-positive HER2-negative metastatic breast cancer after 2 or more therapies [ID4033]
Technology appraisal guidance
TBC
Secukinumab for treating enthesitis-related arthritis or juvenile psoriatic arthritis [ID3738]
Technology appraisal guidance
TBC
Selective internal radiation therapy with QuiremSpheres for treating unresectable advanced hepatocellular carcinoma (Partial review of TA688) [ID6376]
Technology appraisal guidance
3 July 2024
Selinexor with bortezomib and low-dose dexamethasone for treating relapsed refractory multiple myeloma [ID3797]
Technology appraisal guidance
15 May 2024
Selpercatinib for advanced thyroid cancer with RET alterations that has not been treated with systemic therapy [ID6132]
Technology appraisal guidance
21 August 2024
Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer (MA review of TA760) [ID6293]
Technology appraisal guidance
13 November 2024
Selpercatinib for untreated RET-positive advanced thyroid cancer [ID6183]
Technology appraisal guidance
TBC
Setmelanotide for treating obesity and hyperphagia in Bardet-Biedl syndrome [ID3947]
Technology appraisal guidance
22 May 2024
Sipavibart for preventing COVID 19 [ID6282]
Technology appraisal guidance
26 February 2025
Sirolimus for treating angiofibroma from tuberous sclerosis complex in people 6 years and older [ID3990]
Technology appraisal guidance
18 September 2024
Sodium phenylbutyrate–ursodoxicoltaurine for treating amyotrophic lateral sclerosis [ID6246]
Technology appraisal guidance
TBC
Somapacitan for treating growth hormone deficiency in children [ID6178]
Technology appraisal guidance
TBC
Sotatercept for treating pulmonary arterial hypertension [ID6163]
Technology appraisal guidance
TBC
Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (MA review of TA781) [ID6287]
Technology appraisal guidance
26 February 2025
Sparsentan for treating primary IgA nephropathy ID6308
Technology appraisal guidance
11 December 2024
Spartalizumab with dabrafenib and trametinib for untreated BRAF V600 mutation-positive unresectable or metastatic melanoma [ID1668]
Technology appraisal guidance
21 April 2021
Previous page
1
3
4
Current page
5
6
Page
5
of
6
Next page
Results per page
10
25
50
All
Back to top